GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChemoCentryx Inc (NAS:CCXI) » Definitions » Shiller PE Ratio

ChemoCentryx (ChemoCentryx) Shiller PE Ratio : (As of Apr. 26, 2024)


View and export this data going back to 2012. Start your Free Trial

What is ChemoCentryx Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


ChemoCentryx Shiller PE Ratio Historical Data

The historical data trend for ChemoCentryx's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChemoCentryx Shiller PE Ratio Chart

ChemoCentryx Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ChemoCentryx Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ChemoCentryx's Shiller PE Ratio

For the Biotechnology subindustry, ChemoCentryx's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ChemoCentryx's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ChemoCentryx's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ChemoCentryx's Shiller PE Ratio falls into.



ChemoCentryx Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

ChemoCentryx's E10 for the quarter that ended in Jun. 2022 is calculated as:

For example, ChemoCentryx's adjusted earnings per share data for the three months ended in Jun. 2022 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2022 (Change)*Current CPI (Jun. 2022)
=-0.44/125.0168*125.0168
=-0.440

Current CPI (Jun. 2022) = 125.0168.

ChemoCentryx Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201209 -0.280 97.633 -0.359
201212 -0.280 96.871 -0.361
201303 -0.280 98.209 -0.356
201306 -0.230 98.518 -0.292
201309 -0.220 98.790 -0.278
201312 -0.220 98.326 -0.280
201403 -0.270 99.695 -0.339
201406 -0.280 100.560 -0.348
201409 -0.250 100.428 -0.311
201412 -0.280 99.070 -0.353
201503 -0.280 99.621 -0.351
201506 -0.280 100.684 -0.348
201509 -0.260 100.392 -0.324
201512 -0.260 99.792 -0.326
201603 -0.340 100.470 -0.423
201606 -0.220 101.688 -0.270
201609 -0.150 101.861 -0.184
201612 -0.160 101.863 -0.196
201703 -0.120 102.862 -0.146
201706 -0.190 103.349 -0.230
201709 -0.130 104.136 -0.156
201712 0.800 104.011 0.962
201803 -0.190 105.290 -0.226
201806 -0.140 106.317 -0.165
201809 -0.220 106.507 -0.258
201812 -0.210 105.998 -0.248
201903 -0.230 107.251 -0.268
201906 -0.260 108.070 -0.301
201909 -0.220 108.329 -0.254
201912 -0.260 108.420 -0.300
202003 -0.350 108.902 -0.402
202006 0.290 108.767 0.333
202009 -0.350 109.815 -0.398
202012 -0.430 109.897 -0.489
202103 -0.430 111.754 -0.481
202106 -0.560 114.631 -0.611
202109 -0.320 115.734 -0.346
202112 -0.580 117.630 -0.616
202203 -0.550 121.301 -0.567
202206 -0.440 125.017 -0.440

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ChemoCentryx  (NAS:CCXI) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


ChemoCentryx Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of ChemoCentryx's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ChemoCentryx (ChemoCentryx) Business Description

Traded in Other Exchanges
N/A
Address
835 Industrial Road, Suite 600, San Carlos, CA, USA, 94070
ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.
Executives
Susan M Kanaya officer: SVP Finance, CFO & Secretary 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Thomas J. Schall director, 10 percent owner, officer: President, CEO and Director 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Jennifer Lyn Herron director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
James L Tyree director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
Yi Ching Yau officer: SVP, Finance & Acctg Officer C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
David E. Wheadon director C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Vifor (international) Ltd 10 percent owner RECHENSTRASSE 37, ST. GALLEN V8 9000
Tausif Butt officer: EVP, Chief Operating Officer C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Geoffrey M. Parker director 15 RIORDAN PLACE, MENLO PARK CA 94025
Thomas A. Edwards director C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Markus J. Cappel officer: CBO and Treasurer 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Pui San Kwan officer: Principal Acctg Officer 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Rajinder Singh officer: SVP, Research C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vifor Pharma Ltd. 10 percent owner UNTERMATTWEG 8, BERNE V8 CH-3027

ChemoCentryx (ChemoCentryx) Headlines

From GuruFocus